Lupus & antiphospholipid syndrome
Validity of immunoglobulin-binding protein 1 as a biomarker for lupus nephritis
Authors' conclusion
The serum IGBP1 levels were high in patients with LN and were positively correlated with the pathologic activity index. The serum IGBP1 level of 547.45 ng/mL is a valid biomarker for detecting active nephritis.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) (SLICC criteria) with and without lupus nephritis (LN), and controls3 groups
- Participants
- 96 patients
- Comparison
- Serum IGBP1 in LN vs SLE without nephritis vs controls
- Outcome
- Validity of serum IGBP1 (enzyme-linked immunosorbent assay (ELISA)) as a biomarker for LN; relation to SLE disease activity and renal activity
Methodological detailscase-control
- Case-control
Performance
As reported in the abstract
Serum IGBP1 for detecting active nephritis (vs renal SLEDAI)
| Test or model | Cut-off | Sensitivity | Specificity |
|---|---|---|---|
| Nephritis | 547.45 ng/mL | 93.8% | 96.9% |
Nephritis
Cut-off547.45 ng/mL
Sensitivity93.8%
Specificity96.9%
- Nephritis and nonnephritis groups had higher IGBP1 than controls; nephritis highest
- P < 0.001
Further findings
Correlation of IGBP1 with proteinuria in nephritis group
- R = 0.568
- P = 0.001
Correlation of IGBP1 with renal SLEDAI in nephritis group
- R = 0.475
- P = 0.006
Correlation of IGBP1 with SLEDAI-2K
- Non-significant in both nephritis and nonnephritis groups
IGBP1 across histopathologic classes
- Significantly different among classes; class V highest
- P < 0.001
- Significant positive correlation with pathologic activity index
Original publication
Validity of immunoglobulin-binding protein 1 as a biomarker for lupus nephritis. Lupus. Published 23 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →